Eric Masson

Company: Arvinas

Job title: Senior Vice President - Early Clinical Development

Seminars:

Fireside Chat: Navigating the Future Development of Protein Degraders for CNS & Making the Most of Early Industry Collaboration 1:45 pm

To what extent are gaps in biological understanding hampering development of CNS protein degraders? What are the short to medium term barriers to overcome to accelerate CNS degrader development on par with oncology? How can the drug development community collaborate and mutually benefit in exploring TPD applications to CNS?Read more

day: Conference Day Two

Navigating the Crucial Clinical Trial Design Considerations for CNS Protein Degraders 9:00 am

Outlining experiences of carrying out long-lasting clinical trials for neurodegenerative indications with older patient populations Overcoming dosage and toxicology considerations before entering clinical trials Discussing the use of biomarkers to monitor brain penetration, target engagement and degradation efficacyRead more

day: Conference Day One